121 related articles for article (PubMed ID: 17314073)
1. Antioxidant therapy for severe cardiac failure induced by iron overload secondary to dyserythropoietic anaemia.
van der Merwe J; Leong JY; Kaye D; Opat S; Bergin PJ; Taylor AJ; Rosenfeldt F
Heart Lung Circ; 2007 Oct; 16(5):394-7. PubMed ID: 17314073
[TBL] [Abstract][Full Text] [Related]
2. Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Buchbinder D; Nugent D; Vu D; Soni A; Stites J; Hsieh L; Puthenveetil G
Pediatr Transplant; 2012 May; 16(3):E69-73. PubMed ID: 21108711
[TBL] [Abstract][Full Text] [Related]
3. Remission from transfusion-dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation.
Bergmann AK; Tamary H; Neufeld EJ
Pediatr Blood Cancer; 2009 Dec; 53(6):1167-8. PubMed ID: 19606459
[No Abstract] [Full Text] [Related]
4. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
5. Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I.
Lavabre-Bertrand T; Ramos J; Delfour C; Henry L; Guiraud I; Carillo S; Wagner A; Bureau JP; Blanc P
Eur J Haematol; 2004 Nov; 73(5):380-3. PubMed ID: 15458519
[TBL] [Abstract][Full Text] [Related]
6. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
7. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Ault P; Jones K
Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
[TBL] [Abstract][Full Text] [Related]
8. [Rare indications for iron chelation therapy with desferrioxamine].
Schmitt K; Tulzer W
Padiatr Padol; 1991; 26(4):199-202. PubMed ID: 1749630
[TBL] [Abstract][Full Text] [Related]
9. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
[TBL] [Abstract][Full Text] [Related]
10. [Secondary iron overload].
Galacteros F
Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():44-8. PubMed ID: 9827215
[No Abstract] [Full Text] [Related]
11. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia.
Shalev H; Quider AA; Harosh MB; Kapelushnik J
Pediatr Hematol Oncol; 2016; 33(7-8):457-461. PubMed ID: 27960647
[TBL] [Abstract][Full Text] [Related]
12. Congestive heart failure and treatment in thalassemia major.
Aessopos A; Kati M; Tsironi M
Hemoglobin; 2008; 32(1-2):63-73. PubMed ID: 18274984
[TBL] [Abstract][Full Text] [Related]
13. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
14. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
15. Role of T2* magnetic resonance in monitoring iron chelation therapy.
Carpenter JP; Pennell DJ
Acta Haematol; 2009; 122(2-3):146-54. PubMed ID: 19907152
[TBL] [Abstract][Full Text] [Related]
16. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
17. Successful management of congenital dyserythropoietic anemia type I with interferon alpha in a child.
Yarali N; Fişgin T; Duru F; Atilla P; Müftüoğlu SF; Kaymaz SF
Pediatr Hematol Oncol; 2005 Jun; 22(4):265-70. PubMed ID: 16020112
[TBL] [Abstract][Full Text] [Related]
18. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
19. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.
Cazzola M; Barosi G; Bergamaschi G; Dezza L; Palestra P; Polino G; Ramella S; Spriano P; Ascari E
Br J Haematol; 1983 Aug; 54(4):649-54. PubMed ID: 6871111
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
